NCT05017753 (TAP-IT) is a NA clinical trial of Thoracentesis in Heart Failure, sponsored by Bispebjerg Hospital.

Who is sponsoring NCT05017753?

NCT05017753 is sponsored by Bispebjerg Hospital.

What drugs are being tested in NCT05017753?

Interventions in NCT05017753: Thoracentesis, Standard-of-care medical treatment.

What condition does NCT05017753 study?

NCT05017753 studies Heart Failure, Pleural Effusion.

Is NCT05017753 still recruiting?

NCT05017753 is currently completed. Last updated 13 December 2024.

Last reviewed 2024-12-13 · How we verify

NCT05017753: TAP-IT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Thoracentesis to Alleviate Cardiac Pleural Effusion

Completed NA Last updated 13 December 2024

What this trial tests

NA trial testing Thoracentesis in Heart Failure in 135 participants. Completed in 11 December 2024.

Timeline

31 August 2021

Primary endpoint
22 March 2024

11 December 2024

Quick facts

Lead sponsor	Bispebjerg Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	135
Start date	31 August 2021
Primary completion	22 March 2024
Estimated completion	11 December 2024
Sites	10 locations across Denmark

Drugs / interventions tested

Thoracentesis
Standard-of-care medical treatment — full drug profile →

Conditions studied

Heart Failure — all drugs for Heart Failure →
Pleural Effusion — all drugs for Pleural Effusion →

Sponsor

Bispebjerg Hospital

Who can join

18 and older, any sex, with Heart Failure or Pleural Effusion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study will examine the comparative effectiveness of two treatment strategies currently used in the treatment of patients with systolic heart failure presenting with pleural effusion. Patients will be randomized to standard medical treatment only or medical treatment and referral to thoracentesis. Study hypothesis: A strategy of referring patients with heart failure-related pleural effusion to thoracentesis increases number of days alive outside of hospital over the following 90 days.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Cardiac related pleural effusions: a narrative review.
Wijayaratne T, Yousuf A, Panchal R. · · 2024 · cited 9× · PMID 38505011 · DOI 10.21037/jtd-23-1731
A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure.
Glargaard S, Thomsen JH, Tuxen C, Lindholm MG, et al · · 2025 · cited 4× · PMID 40166829 · DOI 10.1161/circulationaha.124.073521
Thoracentesis to alleviate pleural effusion in acute heart failure: study protocol for the multicentre, open-label, randomised controlled TAP-IT trial.
Glargaard S, Thomsen JH, Løgstrup BB, Schou M, et al · · 2024 · cited 4× · PMID 38245015 · DOI 10.1136/bmjopen-2023-078155

Verify or expand the search:

Other trials of Thoracentesis

Trials testing the same drug.

NCT06657638 — Cytological Examination of Malignant Pleural Effusion in Breast Cancer · completed
NCT04236037 — Ultrasound-guided Biopsy of the Pleura as a Supplement to Extraction of Fluid in Patients With One-sided Fluid in the Pl · NA · terminated

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting

Other Bispebjerg Hospital trials

Trials by the same sponsor.

NCT06872060 — The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance. · NA · not yet recruiting
NCT07373587 — Preventing Hospital Associated Disability in Older Patients: Individualized Nutrition and Exercise Strategy · NA · not yet recruiting
NCT07123558 — Anal Cancer Prevention in High-Risk Categories of Men Who Have Sex With Men · NA · not yet recruiting
NCT07124338 — Preventing Hospital Associated Disability in Older Patients: Individualized Nutrition and Exercise Strategy, a Feasibili · NA · active not recruiting
NCT07096648 — Alert Burden When Monitoring Patients at Home · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05017753 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bispebjerg Hospital
Last refreshed: 13 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05017753.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing